FindTrial
Sign In

Evacetrapib

DRUG20 trials

Sponsors

Eli Lilly and Company

Conditions

Cardiovascular DiseaseCardiovascular DiseasesDyslipidemiaHealthyHealthy VolunteersHepatic InsufficiencyHypercholesterolemiaHyperlipidemia

Phase 1

A Study of Evacetrapib in Healthy Participants
CompletedNCT01736254
Eli Lilly and CompanyHealthy Volunteers
Start: 2012-12-31End: 2013-02-28Updated: 2018-10-03
A Study of Evacetrapib in Healthy Female Participants
CompletedNCT01746732
Eli Lilly and CompanyHealthy Volunteers
Start: 2012-12-31End: 2013-05-31Updated: 2018-10-09
Study of Food on Evacetrapib (LY2484595) in Healthy Participants
CompletedNCT01810432
Eli Lilly and CompanyHealthy Volunteers
Start: 2013-03-31End: 2013-06-30Updated: 2018-10-12
A Study of Evacetrapib (LY2484595) in Participants With Severe Renal Impairment and in Healthy Participants
CompletedNCT01825889
Eli Lilly and CompanyCardiovascular Disease
Start: 2013-04-30End: 2013-10-31Updated: 2018-10-09
A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
CompletedNCT01825876
Eli Lilly and CompanyHealthy Volunteers
Start: 2013-04-30End: 2013-06-30Updated: 2018-10-09
A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
CompletedNCT01836185
Eli Lilly and CompanyHepatic Insufficiency
Start: 2013-04-30End: 2013-10-31Updated: 2018-10-12
A Study of Evacetrapib and Digoxin in Healthy Participants
CompletedNCT01897493
Eli Lilly and CompanyHealthy Volunteers
Start: 2013-07-31End: 2013-09-30Updated: 2018-10-09
A Study of Evacetrapib (LY2484595) in Healthy Participants
CompletedNCT01903434
Eli Lilly and CompanyHealthy Volunteers
Start: 2013-07-31End: 2013-11-30Updated: 2018-10-09
A Study of Evacetrapib and Rifampin in Healthy Participants
CompletedNCT01908582
Eli Lilly and CompanyHealthy Volunteers
Start: 2013-07-31End: 2013-09-30Updated: 2018-10-03
A Study of Evacetrapib in Japanese and Non-Japanese Participants
CompletedNCT01958489
Eli Lilly and CompanyHealthy Volunteers
Start: 2013-10-31End: 2014-01-31Updated: 2018-10-09
A Study of Evacetrapib With Selected Statins in Healthy Chinese Participants
CompletedNCT02156492
Eli Lilly and CompanyHealthy Volunteers
Start: 2014-06-30End: 2014-12-31Updated: 2018-10-10
Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
CompletedNCT02161731
Eli Lilly and CompanyHealthy Volunteers
Start: 2014-06-30End: 2014-09-30Updated: 2018-10-03
A Study of Evacetrapib in Participants With Abnormal Cholesterol
CompletedNCT02168803
Eli Lilly and CompanyDyslipidemia
Start: 2014-05-31End: 2015-12-31Updated: 2018-10-03
A Study of Evacetrapib in Healthy Japanese Participants
CompletedNCT02226653
Eli Lilly and CompanyHealthy Volunteers
Start: 2014-09-30End: 2015-04-30Updated: 2018-11-08
A Study to Evaluate the Effect of Increased Stomach pH on Evacetrapib in Healthy Participants
CompletedNCT02365558
Eli Lilly and CompanyHealthy
Start: 2015-01-31End: 2015-04-30Updated: 2018-10-03
A Study of Different Particle Sizes of Evacetrapib in Healthy Participants
CompletedNCT02497391
Eli Lilly and CompanyHealthy
Start: 2015-07-31End: 2015-11-30Updated: 2018-12-03

Phase 3

A Study of Evacetrapib in High-Risk Vascular Disease
TerminatedNCT01687998
Eli Lilly and CompanyCardiovascular Diseases
Start: 2012-10-31End: 2016-07-31Updated: 2019-10-08
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
TerminatedNCT02227784
Eli Lilly and CompanyHyperlipidemia
Start: 2014-10-31End: 2015-12-31Updated: 2019-10-08
A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia
TerminatedNCT02260635
Eli Lilly and CompanyHypercholesterolemia
Start: 2014-11-30End: 2015-12-31Updated: 2018-10-09
A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia
TerminatedNCT02260648
Eli Lilly and CompanyHypercholesterolemia
Start: 2015-01-31End: 2015-11-30Updated: 2018-10-09

Related Papers

Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease
JAMA Cardiology2020-07-08112 citations
Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy.
2019-12-1913 citations
Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With High-Risk Vascular Disease: Insights From the ACCELERATE Trial.
2019-11-223 citations
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease
New England Journal of Medicine2017-05-17768 citations